Title of cohort

    Malmö Preventive Project

    Acronym for cohort

    MPP

    Name of Principal Investigator - Title

    Prof

    Name of Principal Investigator - First name

    Olle

    Name of Principal Investigator - Last name

    Melander

    Address of institution -Institution

    Dept of Clinical Sciences, Malmö

    Address of institution - Street address

    Jan Waldenströms gata 35

    Address of institution - City

    Malmö

    Address of institution - Postcode

    20502

    Country

    Sweden

    Contact email
    Funding source

    Q1a. Please indicate below if your cohort includes or expects to include, incidence of the following conditions?

    Alzheimer's disease and other dementias

    Q1b. When are studies on the above condition(s) expected to become possible?

    2016-2020

    Q2a. In a single sentence what is the stated aim of the cohort?

    MPP started as a primary prevention project at the Medical Clinic in Malmö, with focus on improvement of health of industrial workers

    Q2b. What distinguishes this cohort from other population cohorts?

    It is one of the largest prospective cohorts in Sweden

    Q3a. i) Number of publications that involve use of your cohort to date

    >1000

    Q3a.ii) Please give up to three examples of studies to date (Principal Investigator, Institution, Title of Study)

    Q3b. If data on research outputs are already available please paste the publication list/other data or provide a link to where these data are publicly available

    Nilsson ED, Melander O, Elmståhl S, Lethagen E, Minthon L, Pihlsgård M, Nägga K. Copeptin, a Marker of Vasopressin, Predicts Vascular Dementia but not Alzheimer's Disease. J Alzheimers Dis. 2016 Apr 12;52(3):1047-53

    Q3c. If no research has been done as yet, please explain in a few sentences what information (i.e. research findings) you expect will be gained from the population

    Q4a. Study criteria: what is the age range of participants at recruitment? Age in years From:

    26

    Q4a. Study criteria: what is the age range of participants at recruitment? To:

    61

    Q4b. Study criteria: what are the inclusion criteria?

    Residents in Malmö, born 1921-1949, initially only men were invited but later on also women

    Q4c. Study criteria: what are the exclusion criteria?

    Q5. What is the size of the cohort (i.e. how many participants have enrolled)?

    More than 15,000 participants

    Q6a. Please describe what measures are used to characterise participants

    Data are obtained from questionnaries, analyses of blood samples, national and local registers

    Q6b. Are there additional measures for participants with a clinical disorder?

    Yes, but only in conjunction with the screening

    Q6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)?

    Yes

    If yes please specify

    Primarily cancer, cardiovascular diseases and diabetes, Dementia

    Q7. What is the study design (select all that apply)?

    Prospective cohort|Longitudinal

    Q8. Are your cases matched by

    Other health assessment

    Q9a. Does your study include a specialised subset of control participants?

    No

    Q9b. If your study includes a specialised subset of control participants please describe

    Q10a. i) Please enter the data collection start date

    Screening started in 1974, but data before that date are obtained from national and local registries

    Q10a. ii) Please enter the data collection end date

    Currently we have follow-up data until Dec 31, 2014

    Q10a. iii) Is data collection for this study

    Data analysis ongoing|Closed to new patients

    Q10b. If data collection is ongoing, are there plans to continue the cohort study beyond the current projected end date?

    Q11. Is data collected

    Through links to other records or registers (e.g dental records, police records etc)

    Other please specify here

    National medical and population registers (SoS, SCB), Tax authority etc

    Q12. Is there a system in place to enable re-contact with patients to ask about participation in future studies?

    No

    Q13a. Please give information on the format and availability of data stored in a database (1)

    % available

    Q13a. Please give information on the format and availability of data stored in a database (2)

    % available

    Q13a. Please give information on the format and availability of data stored in a database (3)

    % available

    Q13a. Please give information on the format and availability of data stored in a database (4)

    % available

    Other (please specify)

    % available

    Q13b. Please give information on the format and availability of data held as individual records (1)

    Data is held as individual records

    % available

    100

    Q13b. Please give information on the format and availability of data held as individual records (2)

    No

    % available

    Q13b. Please give information on the format and availability of data held as individual records (3)

    Data held on computer based records

    % available

    100

    Q13b. Please give information on the format and availability of data held as individual records (4)

    % available

    Please specify language used

    English, Swedish

    Q14a. Is data available to other groups?

    Yes

    Q14b. If data is available to other groups what is the access policy/mechanisms for access?

    Apply to PI or co-ordinator at resource|Access committee mechanism|Local/ regional access|National access|International access|Access to industry|Access for pilot studies permitted|Applicant needs to provide separate external ethics approval|Resource has own ethics approval so usually no need for separate external ethics approval

    Q15. What data sharing policy is specified as a condition of use?

    Data made publicly available after a specified time point

    Q16a. Are tissues/samples/DNA available to other groups?

    Yes

    Q16b i) If yes, please describe below:

    Living donors: blood derivatives|Living donors: DNA

    Q16b. ii) In what form are tissues/samples/DNA supplied?

    Secondary samples:(derivatives of primary samples)|Secondary samples: plasma|Secondary samples: DNA

    Q16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data (Q14 above)?

    Yes

    Q17. Is information on biological characteristics available to other groups?

    Yes, for all the cohort

    Number of Patients

    % of total cohort

Types: Population Cohorts
Member States: Sweden
Diseases: Alzheimer's disease & other dementias
Years: 2016
Database Categories: N/A
Database Tags: N/A

Export as PDF